Uncategorized Archives - BioMedWire (BMW)

TuesdayApr 29, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…

FridayApr 25, 2025 10:30 am

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive transition to value-based care. The company’s patented analytics engine predicts revenue performance and simplifies contract reimbursement analysis to maximize financial efficiency. Adageis acts as an advocate for providers, helping them understand what payments they should expect from insurers. The platform integrates with over 90 EHR systems and supports providers through improved cash flow and access to funding. With growing adoption, Adageis continues to expand investor partnerships and develop superior tools for smaller healthcare practices. Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of…

TuesdayApr 22, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch Strategic sports partnership with Charlotte FC boosts brand visibility and community presence Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number…

MondayApr 21, 2025 1:00 pm

Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat

An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments. Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate. Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants. Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases…

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 10:45 am

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to quality care, in profitable shift from fee-for-service to value-based models. Its system helps decipher complex insurance contracts to maximize reimbursements. The software helps decipher complex insurance contracts to maximize reimbursements, integrating smoothly with major electronic health record systems to identify high-risk patients and care gaps. Adageis is continuously working with investors to expand its offerings for a growing list of small and independent practices. Adageis, a forward-thinking healthcare technology company focused on value-based care solutions, is helping clinics and medical groups measure how their delivery…

TuesdayApr 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Recent Zacks report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix. The Zacks report underscores Soligenix's strategic focus on rare diseases and areas lacking effective treatments. Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix's diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.…

FridayApr 04, 2025 10:30 am

Adageis Offers Enhanced Transparency in Insurance Payments for Healthcare Providers

The company’s AI-driven software helps clinics transition to value-based care and optimize revenue streams, offering providers superior visibility into insurance contracts and associated reimbursements. Adageis provides advocacy for healthcare organizations, identifying discrepancies in payments and ensuring they are fairly compensated for services. The platform allows providers to assess which insurance contracts align best with their financial goals and patient care priorities, improving financial planning. Healthcare providers often struggle to navigate complex insurance contracts to determine whether they are receiving proper reimbursement for services. A lack of transparency in how the process unfolds can result in lost revenue and financial instability,…

ThursdayApr 03, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Adageis Offers Enhanced Transparency in Insurance Payments for Healthcare Providers

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search